Evidence map›Paper›PMID 40767943›Full record

ArticleLasers in medical science2025

Combining photobiomodulation and naringenin for treatment of asthenozoospermia: A promising therapeutic approach.

Ali Moradi, Hamid Nazarian, Zahra Shams Mofarahe, Mahsa Kazemi, Hamidreza Mosleh, Mahsa Ghaffari Novin, Seyed Kamran Ghomeshi, Sufan Chien, Mohammad Bayat, Marefat Ghaffari Novin

Abstract read
PubMed Publisher
In one paragraph

Article in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ali Moradi *Department of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0003-4169-0354
Hamid Nazarian *Department of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Zahra Shams MofaraheDepartment of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mahsa KazemiDepartment of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hamidreza MoslehDepartment of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mahsa Ghaffari NovinDepartment of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Seyed Kamran GhomeshiDepartment of Statistics, University of Qom, Qom, Iran.
Sufan ChienPrice Institute of Surgical Research, University of Louisville and Noveratech LLC of Louisville, Louisville, KY, USA.
Mohammad BayatPrice Institute of Surgical Research, University of Louisville and Noveratech LLC of Louisville, Louisville, KY, USA. bayat_m@yahoo.com.ORCID http://orcid.org/0000-0001-5214-4223
Marefat Ghaffari NovinDepartment of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. mghaffarin@yahoo.com.

Funding

Research Department of the medical faculty, School of medicine, Shahid Beheshti University of Medical Sciences. 43005026
6 · The paper itself

Abstract

Asthenozoospermia (AZS) affects approximately 20% of males. We aimed to determine the effectiveness of different photobiomodulation (PBM) protocols and naringenin (NAR) alone and in combination on sperm motility (SM) in AZS patients in vitro. We studied the different PBM protocols, including 0.6, 1.2, and 2.4 J/cm

Indexed as

AsthenozoospermiaFlavanonesLow-Level Light TherapyAdultCombined Modality TherapyDNA FragmentationHumansMaleSpermatozoaSperm MotilityFlavanonesnaringeninAsthenozoospermiaHumanNaringeninPhotobiomodulationSemenSperm motility

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.